With increasing fatalities due to chronic respiratory disorders worldwide, the demand for respiratory inhaler devices is anticipated to ramp-up in coming years. The respiratory inhaler devices help in effective delivery of medication directly into the airway to lungs. With rising level of pollutants in the air, the number of patients suffering with asthma and COPD has increased significantly over last decade.
According to the Forum of International Respiratory Societies data, close to 350 million people were suffering from asthma and an approximate of 65 million people were suffer with chronic obstructive pulmonary disease (COPD) till 2017. The number of people suffering with asthma and COPD is anticipated to increase significantly in coming years. The global respiratory inhaler devices market is expected to grow at a steady compound annual growth rate during the forecast period.
North America contributed the largest share to the global respiratory inhaler devices market in 2019 owing to high prevalence of chronic respiratory diseases with major impact of Asthma and COPD. North America is anticipated to stay dominant throughout the forecast period due to increasing incidences of Chronic Obstructive Pulmonary Disease (COPD) in the United States. Asia Pacific respiratory inhaler devices market offers significant opportunities to the manufacturers of respiratory inhaler devices owing to government initiatives and rising spending on medical device manufacturing in China, India, Japan, Malaysia and Singapore. Additionally, increasing incidences of chronic respiratory diseases across the region is anticipated to contribute toward the growth of respirator inhaler devices market.
The report titled “Respiratory Inhaler Devices Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global respiratory inhaler devices market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Koninklijke Philips N.V. reported revenues of USD 21.52 billion in 2019 and the product segment analysis of the company indicates that Diagnosis & Treatment business segment of the company dominated revenue in 2019.
The global respiratory inhaler devices market is segmented based on product type, technology, disease type, and geography. Based on product type, the global respiratory inhaler devices market is segmented into dry powder inhaler, metered dose inhaler, and nebulizer. The nebulizers are further sub-segmented into ultrasonic nebulizer, compressed air nebulizer, and mesh nebulizer. Based on technology, the global respiratory inhaler devices market is segmented into manually operated inhaler devices, and digitally operated inhaler devices. Based on disease type, the global respiratory inhaler devices market is segmented into asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and others. Based on geography, the global Respiratory Inhaler Devices market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
Additionally, the study provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on respiratory inhaler devices. Further, market share of prominent companies in the global respiratory inhaler devices market would also be estimated. For instance, Koninklijke Philips N.V. operates through four Diagnosis & Treatment, Connected Care, Personal Health, and Others. The respiratory inhaler devices are delivered under the Connected Care (Sleep & Respiratory Care) business segment of the company with revenue contribution of US$ 5,157.8 million in 2019.
The research would provide key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the respiratory inhaler device manufacturing companies. Furthermore, the global respiratory inhaler devices market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the Respiratory Inhaler Devices market business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global respiratory inhaler devices market.
Major players active in the global respiratory inhaler devices market include AstraZeneca plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.
By Product type
- dry powder inhaler
- metered dose inhaler
- manually operated inhaler devices
- digitally operated inhaler devices
By Disease type
- chronic obstructive pulmonary disease (COPD)
- pulmonary arterial hypertension
- North America
- South America
- Middle East and Africa